Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neurofibromatosis 1 2 Glioma 2 Colorectal Neoplasms 2 Vascular Malformations 1 Skin Diseases, Vascular 1 Primary Malignant Peripheral Nerve Sheath Tumors 1 Oligodendroglioma 1 Neurofibromatoses 1 Neurofibroma 1 Neurocytoma 1 Neoplasms, Neuroepithelial 1 NF1 1 Melanoma 1 Lymphatic Abnormalities 1 Lymphangioma, Cystic 1 Lymphangioma 1 Liposarcoma, Myxoid 1 Liposarcoma 1 KRAS Mutant Non-Small Cell Lung Cancer 1 Glioblastoma 1 Ganglioneuroma 1 Ganglioglioma 1 Central Nervous System Neoplasms 1 Breast Neoplasms 1 Astrocytoma 1 Arteriovenous Malformations 1

Interventions

talimogene laherparepvec 1 peginterferon alfa-2b 1 nilotinib 1 mirdametinib 1 binimetinib 1 antineoplaston AS 2-1 1 antineoplaston A10 1 Vincristine 1 Temozolomide 1 Talaporfin 1 Sirolimus 1 Restraint, Physical 1 Ranibizumab 1 Radiosurgery 1 Photochemotherapy 1 Neurofibromin 1 1 Imatinib Mesylate 1 Everolimus 1 Elasticity Imaging Techniques 1 Deoxycholic Acid 1 Cryotherapy 1 Celecoxib 1 Aminolevulinic Acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Neurofibroma × mirdametinib × Clear all

NCT02096471 2019-01-10

MEK Inhibitor

University of Alabama at Birmingham

Phase 2 Completed

19 enrolled 14 charts

Neurofibroma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡